Janet Grove
Director/Board Member bei INMED PHARMACEUTICALS INC.
Vermögen: - $ am 31.03.2024
Profil
Janet P.
Grove is currently an Independent Director at InMed Pharmaceuticals, Inc. and a Director at Genome British Columbia and Phoenix Molecular Designs Ltd.
She previously worked as Vice President at QLT, Inc. and as a Partner at Norton Rose Fulbright Canada LLP.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 23.12.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Janet Grove
| Unternehmen | Position | Beginn |
|---|---|---|
| INMED PHARMACEUTICALS INC. | Director/Board Member | 11.02.2022 |
Phoenix Molecular Designs Ltd.
 Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | Director/Board Member | - |
Genome British Columbia
 Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Director/Board Member | - |
Ehemalige bekannte Positionen von Janet Grove
| Unternehmen | Position | Ende |
|---|---|---|
Norton Rose Fulbright Canada LLP
 Norton Rose Fulbright Canada LLP Miscellaneous Commercial ServicesCommercial Services Part of Norton Rose Fulbright LLP, Norton Rose Fulbright Canada LLP provides legal services. The private company is based in Québec, Canada. | Corporate Officer/Principal | - |
QLT, Inc.
 QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INMED PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
Genome British Columbia
Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Commercial Services |
Norton Rose Fulbright Canada LLP
Norton Rose Fulbright Canada LLP Miscellaneous Commercial ServicesCommercial Services Part of Norton Rose Fulbright LLP, Norton Rose Fulbright Canada LLP provides legal services. The private company is based in Québec, Canada. | Commercial Services |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | Commercial Services |
